Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,566 Mln
P/E Ratio
2.35
P/B Ratio
1.03
Industry P/E
--
Debt to Equity
0.04
ROE
0.57 %
ROCE
54.31 %
Div. Yield
0 %
Book Value
26.62
EPS
11.64
CFO
$-2,361.63 Mln
EBITDA
$-3,057.53 Mln
Net Profit
$-584.16 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Agios Pharm (AGIO)
| -13.68 | -9.38 | -16.72 | -6.11 | 5.33 | -8.90 | -12.14 |
|
BSE Sensex*
| 1.96 | 3.74 | 4.26 | 8.19 | 11.73 | 20.15 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Agios Pharm (AGIO)
| 47.09 | -20.69 | -14.57 | -24.14 | -9.26 | 3.56 | -19.25 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase... (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 88 Sidney Street, Cambridge, MA, United States, 02139 Read more
CEO & Director
Mr. Brian M. Goff M.B.A.
CEO & Director
Mr. Brian M. Goff M.B.A.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Agios Pharm (AGIO) stood at $ 1,663 Mln as on 31-Dec-24
The share price of Agios Pharm (AGIO) is $28.37 (NASDAQ) as of 23-Apr-2025 16:15 EDT. Agios Pharm (AGIO) has given a return of 5.33% in the last 3 years.
Agios Pharm (AGIO) has a market capitalisation of $ 1,566 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Agios Pharm (AGIO) is 2.35 times as on 22-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Agios Pharm (AGIO) and enter the required number of quantities and click on buy to purchase the shares of Agios Pharm (AGIO).
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 88 Sidney Street, Cambridge, MA, United States, 02139
The CEO & director of Mr. Brian M. Goff M.B.A.. is Agios Pharm (AGIO), and CFO & Sr. VP is Mr. Brian M. Goff M.B.A..
There is no promoter pledging in Agios Pharm (AGIO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Agios Pharm (AGIO) | Ratios |
|---|---|
|
Return on equity(%)
|
57.29
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
1845.92
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Agios Pharm (AGIO) was $0 Mln.
$0.37
(
